Back to mobile site

Acrivon's (ACRV) ORR, mDoR Results are Competitive - Citizens

November 17, 2025 4:27 AM EST Send to a Friend
Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $13.00 price target on Acrivon Therapeutics Inc (NASDAQ: ACRV).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login